Posted on 10/21/2015 1:40:32 PM PDT by sparklite2
Valeant shares plunged as much as 40 percent after an influential short-seller accused the company of fraud, saying it used its relationship with specialty pharmacies to inflate revenue.
With the stocks dramatic swings, Ackmans portfolio lost as much as $820 million during the day but the loss lessened to roughly $650 million as the price inched up again in mid-afternoon. Cable television station CNBC reported that Ackman bought an additional 2 million shares of Valeant on Wednesday.
(Excerpt) Read more at oann.com ...
I guess no one will ever use the nickname Prince Valeant to describe him, eh?
Riding in with a two million share purchase of a stock that had just lost him almost a billion dollars has to be the sine qua non of “someday my prince will come.” He has big brass ones, but may be another Don Quixote. Time will tell.
Big Brass Ones indeed.
The problem I see, is that if they were “inflating revenue” you are looking at SEC investigations, Federal penalties, and then Civil suits from aggrieved customers and investors. And when the Feds have access to your books, they can then look at anything and everything.
For patients prescribed drugs on Philidor's list I give them a script for them to try filling normally. If they're happy with the way that goes, fine. But if they find their regular pharmacy's price to be higher than they like or if their insurance wants me to fill out a stack of pre-authorization paperwork I tell them we'll instead use Philidor. I have a one page form, personalized with my office's information, that covers all 27 products conceivably of Dermatologic interest. We fill in the drug's name, quantity and directions and the patient's name, phone number, date of birth and zip code. Period! We fax that one page to Philidor and tell the patient to call Philidor later to provide their own shipping, payment and if they have any, insurance, information. Philidor ships out the medication and deals with any insurance on its own. They have two price tiers, one for folks with insurance and a cash only price for those who don't. The former tops at $35 and the latter at $75. My staff reports zero patient complaints to date and it is MUCH easier for us than the usual pre-authorization paperwork run around. I've had a couple other other drug company representatives tell me they intend similar plans, but none have yet provided sufficient details to use them.
The only losers I see at the consumer end are the local pharmacies and their distribution networks. I value them as useful sources of information for my patients and as sometimes invaluable sources of information for me with complicated patients. I don't want to see them hurt, but I strongly value a free market. Until we can get Obama, et al, out of the middle of things this strikes me as a reasonable approach at the consumer end of the business model. Now if they really are cooking the corporate books to make this work at the other end and are thus defrauding investors there may be a problem, one I'm not qualified to specifically evaluate. Although I'm confident getting rid of Obama, his friends, and their policies would greatly reduce the potential for such problems.
“The only losers I see at the consumer end are the local pharmacies and their distribution networks.”
Bypassing the distribution networks seems to be a tempest boiling away. I’m thinking of the hedge fund manager who lost a ton of client money and was fired by the board.
You may remember him from the news a few months ago that he bought the patent or the rights to a drug that was invented back in the fifties and then jacked the price up to the sky, dealing only with hospitals direct. Can’t remember his name.
He probably stopped ‘donating’ his Obama protection bucks. The One keeps those who pay out of trouble and out of the news unless they go WAY over the edge.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.